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Summary 
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, 
VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), 
assessed the risk of “other substances” in food supplements and energy drinks sold in 
Norway. VKM has assessed the risk of doses given by NFSA. These risk assessments will 
provide NFSA with the scientific basis while regulating the addition of “other substances” to 
food supplements and other foods. 
“Other substances” are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional or physiological effect. The substance 
is added mainly to food supplements, but also to energy drinks and other foods. VKM has 
not in this series of risk assessments of “other substances” evaluated any potential beneficial 
effects from these substances, only possible adverse effects. 
The present report is a risk assessment of eicosapentaenoic acid (EPA), docosapentaenoic 
acid (DPA) and docosahexaenoic acid (DHA) in food supplements, and is based on previous 
risk assessments and a literature search.  
It is emphasised that this risk assessment concerns the single fatty acids EPA, DPA or DHA 
separately and not mixtures of these as found in e.g. fish oil/cod liver oil. For risk 
assessment of combined mixtures of n-3 LCPUFAs in e.g. fish oil/cod liver oil, see the EFSA 
opinion from 2012 or the VKM assessment from 2011 (EFSA, 2012; VKM, 2011). In the 
reviewed literature of this risk assessment, no studies investigating ratios between EPA, DPA, 
DHA or other fatty acids in mixtures have been identified.  
EPA, DPA and DHA are long chain n-3 polyunsaturated fatty acids (n-3 LCPUFA) and in food 
these fatty acids are incorporated in triacylglycerols (TAGs) and phospholipids (PLs). Dietary 
sources are fatty fish, cod liver-, seal-, whale-, fish- and krill oils and human milk, containing 
various ratios of these fatty acids in combination. EPA can be metabolised to eicosanoids 
such as prostaglandins, prostacyclins and leukotrienes, all groups are biologically active 
substances. The eicosanoids participate in the regulation of blood pressure, renal function, 
blood coagulation, inflammatory and immunological reactions. DHA is an essential structural 
component of the brain, skin, sperm, testicles and retina. DPA can be retro-converted to EPA 
or converted to DHA. Still little is known of the biological effects of DPA.  
Humans have a limited capacity to synthesise EPA, DPA and subsequently DHA from the 
precursor alpha-linolenic acid (ALA), and this endogenous production is negligible in 
comparison to the doses used in supplementation studies. 
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According to information from the NFSA, EPA, DPA and DHA are food supplement ingredients 
in Norway, and NFSA has requested a risk assessment of these fatty acids in the following 
doses in food supplements:  
EPA: 1500, 1750 and 1825 mg/day 
DPA: 100, 125 and 150 mg/day 
DHA: 1050 and 1290 mg/day 
Children below 10 years were not included in the terms of reference. 
Information about intake of EPA, DPA and DHA from the diet is scarce, but calculations 
performed in the Norwegian Mother and Child Cohort Study indicate a mean total intake (SD) 
from food and supplements of EPA around 330 (340) mg/day, DPA 43 (30) mg/day and DHA 
430 (380) mg/day among pregnant women (2002 to 2008). Mean combined intake of EPA, 
DPA and DHA from fish oil/ cod liver oil in adults participating in a nationally representative 
dietary survey was 735 mg/day (VKM, 2014).  
The major concerns with high intake of EPA and DHA have been increased bleeding time, 
adverse effects related to immune function, lipid peroxidation and glucose homeostasis. 
EFSA concluded in 2012 that long-term supplemental intakes of 5 g/day of the n-3 LCPUFA 
do not raise safety concerns for adults with regard to an increased risk of spontaneous 
bleeding episodes or bleeding complications, or affect glucose homeostasis, immune function 
or lipid peroxidation. In 2011, VKM concluded that an intake n-3 LCPUFA up to 6.9 g/day 
was not associated with increased risk of any serious adverse events.  
Some adverse health effects related to gastrointestinal function, including abdominal cramps, 
flatulence, eructation, vomiting and diarrhea have been reported, but seem to be associated 
with intake of an oily substance and not related specifically to EPA, DPA and/or DHA. 
EPA 
In the report from 2012, EFSA concluded that 1.8 g/day of supplemental EPA does not raise 
safety concerns in adults. None of the included studies from our literature searches limited to 
2012 and onwards have investigated bleeding complications. The dosages of EPA in the 
three included studies in this report range from 1.8 to 3.8 g/day for 12 weeks. The main 
endpoints in the studies included lipid peroxidation, inflammation biomarkers of 
cardiovascular diseases and no serious adverse events were found related to the main 
endpoints. In general, adverse events were described as gastrointestinal discomforts and not 
related to dosage.  
Studies of longer duration are necessary before an intake above 1.8 g of EPA can be 
considered safe.  
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The Norwegian Scientific Committee for Food Safety (VKM) concludes that the specified 
doses of 1500, 1750, 1825 mg/day of EPA in food supplements are unlikely to cause adverse 
health effects in adults (≥18 years). 
In 2012, EFSA did not make conclusions for children or adolescents for EPA. No new studies 
with EPA supplementation have been identified in children or adolescents after 2012, and 
therefore no risk assessment can be made for children (≥10 years) or adolescents. 
DPA 
No dosage of DPA in food supplements can be evaluated due to lack of data. 
DHA 
EFSA concluded that 1 g/day of supplemental DHA does not raise safety concerns for the 
general population (including children and adolescents). The dosages of DHA in the included 
trials in this report range from 1.0 to 3.6 g/day and the duration from five weeks to four 
years. Six out of seven studies have used dosages from 1 to 2 g DHA/day. The last study 
included up to 3.6 g DHA/day for four years and the age spanned from 7 to 31 years. The 
main endpoints in all studies included lipid peroxidation, inflammation, cognitive 
performance, blood pressure and biomarkers of cardiovascular diseases and no serious 
adverse events were found related to the main endpoints. In general, adverse events were 
described as gastrointestinal discomforts and not related to dosage. VKM therefore considers 
that the specified daily doses of DHA that moderately exceed 1 g per day (1050 and 
1290 mg/day) are unlikely to cause adverse health effects in the general population including 
children ≥10 years and adolescents.  
VKM concludes that the specified doses of 1050 and 1290 mg/day of DHA in food 
supplements are unlikely to cause adverse health effects in the general population including 
children (≥10 years), adolescents and adults (≥18 years).  
Short summary: 
The Norwegian Scientific Committee for Food Safety (VKM) has, at the request of the 
Norwegian Food Safety Authority, assessed the risk of eicosapentaenoic acid (EPA), 
docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) in food supplements. VKM 
concludes that: 
 The specified doses of 1500, 1750 or 1825 mg/day of EPA in food supplements are 
unlikely to cause adverse health effects in adults (≥18 years). Due to few studies in 
children and adolescents, no conclusion can be drawn for these groups for EPA. 
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 The specified doses of 1050 and 1290 mg/day of DHA in food supplements are 
unlikely to cause adverse health effects in the general population including children 
(≥10 years), adolescents and adults (≥18 years).  
 No dosage of DPA in food supplements can be evaluated due to lack of data.  
It is emphasised that this risk assessment concerns the single fatty acids EPA, DPA or DHA 
separately and not mixtures of these as found in e.g. fish oil and cod liver oil. 
Key words: Adverse health effect, DHA, docosahexaenoic acid, docosapentaenoic acid, 
DPA, eicosapentaenoic acid, EPA, food supplement, n-3 LCPUFA, negative health effect, 
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Sammendrag på norsk 
På oppdrag for Mattilsynet har Vitenskapskomiteen for mattrygghet (VKM) vurdert risiko ved 
tilsetting av “andre stoffer” i kosttilskudd og energidrikk som selges i Norge. VKM har 
risikovurdert ulike bruksdoser oppgitt fra Mattilsynet. Disse risikovurderingene vil gi 
Mattilsynet et vitenskapelig grunnlag for å regulere “andre stoffer”. 
“Andre stoffer” er stoffer som har en ernæringsmessig eller fysiologisk effekt, og som ikke er 
vitaminer og mineraler. De tilsettes i hovedsak til kosttilskudd, men også til energidrikker og 
andre næringsmidler. I disse risikovurderingene har VKM ikke sett på potensielle gunstige 
helseeffekter, men kun vurdert mulige negative helseeffekter. 
I denne rapporten har VKM vurdert risiko ved eikosapentaensyre (EPA), dokosapentaensyre 
(DPA) og dokosaheksaensyre (DHA) som enkeltfettsyrer i kosttilskudd. Risikovurderingen er 
basert på tidligere risikovurderinger av disse fettsyrene og artikler fra litteratursøk. 
Det understrekes at denne risikovurderingen omhandler de enkelte fettsyrene EPA, DPA og 
DHA hver for seg og ikke blandinger av disse slik som man finner i for eksempel fiskeoljer og 
tran. For risikovurdering av blandinger av n-3 LCPUFAs i feks. fiskeolje/tran, se EFSAs 
rapport fra 2012 eller VKMs vurdering fra 2011 (EFSA, 2012; VKM, 2011). Det er ikke 
avdekket noen studier som har undersøkt ratioer mellom EPA, DPA, DHA eller andre fettsyrer 
i den litteraturen som er gjennomgått i denne risikovurderingen. 
EPA, DPA and DHA er langkjedede flerumettede n-3 fettsyrer (n-3 LCPUFA), og i maten er 
disse inkorporert i triacylglyserol (TAG) eller fosfolipider (PL). Kilder i kosten er fet fisk, 
torskelever-, sel -, hval-, fisk- og krilloljer og morsmelk som inneholder ulike kombinasjoner 
og ratioer av disse fettsyrene. EPA kan omdannes til eikosanoider som prostaglandiner, 
prostasykliner og leukotriener, som alle er grupper av biologisk aktive substanser. 
Eikosanoidene tar del i reguleringen av blodtrykk, nyrefunksjonen og blodkoagulering samt 
inflammatoriske og immunologiske reaksjoner. DHA er en essensiell strukturell komponent i 
hjernen, hud, sæd, testikler og retina. DPA kan re-konverteres til EPA eller omdannes til 
DHA. Fortsatt vet vi lite om de biologiske effektene av DPA. Mennesker har en begrenset 
kapasitet til å syntetisere EPA, DPA og følgelig også DHA fra forløperen alfa-linolensyre 
(ALA), og den endogene produksjonen er ubetydelig sammenlignet med dosene som brukes 
i studier. 
Ifølge informasjon fra Mattilsynet inngår EPA, DPA og DHA som ingredienser i kosttilskudd 
som selges i Norge. Oppdraget fra Mattilsynet var å risikovurdere følgende doser i 
kosttilskudd:  
EPA: 1500, 1750 and 1825 mg/dag 
DPA: 100, 125 and 150 mg/dag 
DHA: 1050 and 1290 mg/dag 
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Barn under 10 år inngår ikke i oppdraget. 
Vi har få data om inntak av EPA, DPA og DHA fra kosten, men beregninger utført i Den 
norske mor og barn-undersøkelsen indikerer at gjennomsnittlig (SD) totalt inntak av EPA fra 
mat og tilskudd er omtrent 330 (340) mg/dag, DPA 43 (30) mg/dag and DHA 430 
(380) mg/dag blant gravide kvinner 2002-2008. Gjennomsnittlig inntak av EPA, DPA og DHA 
fra fiskeolje/tran hos voksne i en landsomfattende kostholdsundersøkelse var 735 mg/dag 
(VKM, 2014).  
Bekymringer over høyt inntak av EPA og DHA har hovedsakelig vært knyttet til økt 
blødningstid eller relatert til immunforsvar, lipidperoksidering og glukose-homeostasen. I 
2012 konkluderte EFSA med at et langvarig inntak av EPA i kombinasjon med DHA opp til 
totalt 5 g/dag fra tilskudd ikke medfører økt risiko for spontane blødninger eller 
blødningskomplikasjoner hos voksne, og heller ikke påvirker glukose-homeostasen, 
immunfunksjon eller lipidperoksidering. I 2011 konkluderte VKM at et inntak opptil totalt 
6,9 g/dag av EPA kombinert med DHA ikke var forbundet med noen alvorlige negative 
helseeffekter. 
Det er rapportert om enkelte negative helseeffekter knyttet til gastrointestinale funksjoner, 
inkludert magekramper, oppblåsthet, oppstøt, oppkast og diaré, men disse ser ut til å være 
forbundet med inntak av olje som sådan, og ikke å være spesifikt knyttet til EPA, DPA 
og/eller DHA. 
EPA 
I rapporten fra 2012 konkluderte EFSA med at 1,8 g/dag av EPA fra tilskudd ikke medfører 
noen helserisiko hos voksne. Ingen av de inkluderte studiene fra våre litteratursøk 
(begrenset tilbake i tid fra og med 2012) har undersøkt blødningskomplikasjoner. Doser av 
EPA i de tre inkluderte studiene i denne rapporten spenner fra 1,8 til 3,8 g EPA/dag og 
intervensjonsperiodene var 12 uker. De inkluderte studiene har undersøkt lipidperoksidering, 
immunfunksjon og glukose- og lipid- homeostase, og ingen av dem har rapportert om 
negative effekter i doser opp til 3,8 g EPA/dag. Generelt er de bivirkningene som er 
rapportert beskrevet som gastrointestinale plager og ikke knyttet til dose.  
Det er behov for studier av lenger varighet før det kan vurderes om inntak av EPA over 1,8 
kan vurderes som trygt.  
VKM konkluderer med at det er usannsynlig at de spesifiserte dosene på 1500, 1750 eller 
1825 mg/dag EPA i kosttilskudd vil forårsake negative helseeffekter hos voksne (≥18 år). 
I 2012 konkluderte ikke EFSA for barn eller ungdom vedrørende EPA. VKM har ikke 
identifisert noen nye kosttilskuddsstudier med EPA til barn eller ungdom, og dermed kan 
heller ikke VKM foreta en risikokarakterisering av EPA for barn (≥10 år) eller unge.  
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DPA 
Ingen av de spesifiserte dosene for DPA i kosttilskudd kan vurderes på grunn av mangel på 
data. 
DHA 
EFSA konkluderte med at 1 g/dag av DHA fra tilskudd ikke medfører noen helserisiko i 
befolkningen generelt inkludert barn og unge. Doser av DHA i de inkluderte studiene i denne 
rapporten spenner fra 1,0 til 3,6 g DHA/dag, og intervensjonsperioden spenner fra fem uker 
til fire år. Seks av syv studier har brukt doser på 1-2 g/dag. En av studiene ga opp til 3,6 g 
DHA/dag i fire år til personer i alderen 7-31 år. De viktigste endepunktene i alle de inkluderte 
studiene omfatter lipidperoksidering, inflammasjon, kognitiv prestasjon, blodtrykk og 
biomarkører for hjerte- og karsykdommer, og det er ikke rapportert om alvorlige negative 
helseeffekter i disse studiene. Generelt er de bivirkningene som er rapportert beskrevet som 
gastrointestinale plager og ikke knyttet til dose. VKM anser at det er usannsynlig at en 
moderat overskridelse over 1 g DHA per dag (1050 og 1029 mg/dag) som enkeltfettsyre i 
tilskudd vil forårsake negative helseeffekter i den generelle befolkningen inkludert barn fra 
(≥10 år) og unge. 
VKM konkluderer med at det er usannsynlig at de spesifiserte dosene på 1050 eller 
1290 mg/dag DHA i kosttilskudd vil forårsake negative helseeffekter i den generelle 
befolkningen inkludert barn (≥10 år), unge og voksne (≥18 år). 
Kort sammendrag til nettmelding: Vitenskapskomiteen for mattrygghet (VKM) har på 
oppdrag for Mattilsynet har vurdert risiko ved inntak av eikosapentaensyre (EPA), 
dokosapentaensyre (DPA) og dokosaheksaensyre (DHA) som enkeltfettsyrer i kosttilskudd. 
VKM konkluderer med at:  
 Det er usannsynlig at de spesifiserte dosene på 1500, 1750 eller 1825 mg/dag av EPA 
i kosttilskudd vil forårsake negative helseeffekter hos voksne (≥18 år). På grunn av få 
studier med barn og unge gir VKM ingen konklusjoner for barn og unge for EPA.  
 Det er usannsynlig at de spesifiserte dosene på 1050 eller 1290 mg/dag DHA i 
kosttilskudd vil forårsake negative helseeffekter i den generelle befolkningen inkludert 
barn (≥10 år), unge og voksne (≥18 år). 
 Ingen doser DPA i kosttilskudd kan evalueres på grunn av mangelfulle data. 
Det understrekes at denne risikovurderingen omhandler de enkelte fettsyrene EPA, DPA og 
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Abbreviations and/or glossary 
Abbreviations 
AA  - arachidonic acid 
ASEAN  - Spanish Agency for Food Safety and Nutrition 
AV  - anisidine value 
bw  - body weight 
COX  - cyclooxygenase 
CRP  - C-reactive protein 
DHA  - docosahexaenoic acid 
DPA  - docosapentaenoic acid (in this report referring to n-3 DPA if not specified as 
n-6 DPA) 
EFSA  - European Food Safety Authority 
EPA  - eicosapentaenoic acid 
HbA1c  - hemoglobin A1c 
HDL  - high density lipoprotein 
HOMA-IR - homeostatis model assessment-insulin resistance  
ICAM  - intercellular adhesion molecule 
IL  - interleukin 
LA  - linoleic acid 
LCPUFA - long-chain polyunsaturated fatty acid 
LDL  - low density lipoprotein 
MDD  - major depressive disorder 
NFSA  - Norwegian Food Safety Authority [Norw.: Mattilsynet] 
OPUS  - Optimal well-being, development and health for Danish children 
PGI  - prostaglandin I also called prostacyclin I 
PPAR  - peroxisome proliferator-activated receptor 
PL  - phospholipid 
PLA2  - phospholipase A2 
PUFA  - polyunsaturated fatty acid 
PV  - peroxide value 
TAG  - triacylglycerol 
TG  - triglyceride 
TNF-alpha - tumor necrosis factor-alpha 
TXA  - thromboxane A 
TXB  - thromboxane B 
UL  - tolerable upper intake level 
VCAM  - vascular cell adhesion molecule 
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VKM  - Norwegian Scientific Committee for Food Safety [Norw.: Vitenskapskomiteen 
for Mattrygghet] 
VLDL  - very low density lipoprotein 
Glossary 
“Other substances”: a substance other than a vitamin or mineral that has a nutritional or 
physiological effect (European Regulation (EC) No. 1925/2006, Article 2; http://eur-
lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32006R1925&from=en).  
“Negative health effect” and “adverse health effect” are broad terms and WHO has 
established the following definition for “adverse effect”: a change in morphology, physiology, 
growth, development, reproduction or life span of an organism, system or (sub)population 
that results in an impairment of functional capacity, an impairment of the capacity to 
compensate for additional stress, or an increase in susceptibility to other influences (WHO, 
1994). 
An adverse event is considered serious if it: 
 results in death 
 is life-threatening 
 requires or prolongs hospitalisation 
 is a congenital anomaly or birth defect 
 is a persistent or significant disability/incapacity 
 is another serious or important medical event 
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Background as provided by the 
Norwegian Food Safety Authority 
“Other substances” are substances other than vitamins and minerals, with a nutritional 
and/or physiological effect on the body. “Other substances” are mainly added to food 
supplements, but these may also be added to other foods and beverages, such as sports 
products and energy drinks. Ingestion of these substances in high amounts presents a 
potential risk for consumers. 
In Norway, a former practice of classification of medicines had constituted an effective 
barrier against the sale of potentially harmful “other substances”. Ever since this practice 
was changed in 2009, it has become challenging to regulate and supervise foods with added 
“other substances”. Meanwhile, in the recent years, the Norwegian market has witnessed a 
marked growth in the sales of products containing “other substances”. In 2011, food 
supplements containing “other substances” constituted more than 50% of the market share. 
While at the EU level, these substances fall under the scope of the European Regulation (EC) 
No. 1925/2006 on the addition of vitamins, minerals and certain other substances to foods 
and the European Regulation (EC) No 258/97 concerning novel foods and novel food 
ingredients, “other substances” remain largely unregulated. In order to ensure safe use of 
“other substances” many countries have regulated their use at a national level. For example, 
Denmark regulates these substances in a positive list i.e. a list of substances with maximal 
daily doses, permitted for use in food supplements and other foods 
(https://www.retsinformation.dk/Forms/R0710.aspx?id=163394).  
NFSA is working on the establishment of a regulation on the addition of “other substances” 
to foods at a national level. The regulation will include a list of substances with permitted 
maximal doses, based on the substances and doses found in products on the Norwegian 
market. NFSA has therefore requested the Norwegian Scientific Committee for Food Safety 
(VKM) to assess the safety of “other substances” found on the Norwegian market. NFSA, in 
consultation with the industry, has compiled a list of “other substances” found in products 
marketed in Norway. Only substances with a purity of minimum 50% or concentrated 40 
times or more have been included in the list. Substances regulated by other legislations like 
those for novel foods, food additives, aromas, foods for special medical purposes, etc. have 
been excluded from the list. 
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Terms of reference as provided by the 
Norwegian Food Safety Authority 
The Norwegian Food Safety Authority (NFSA) requested the Norwegian Scientific Committee 
for Food Safety (VKM) to assess the safety of eicosapentaenoic acid (EPA), docosapentaenoic 
acid (DPA) and docosahexaenoic acid (DHA) at the following doses:  
EPA: 1500, 1750 and 1825 mg/day 
DPA: 100, 125 and 150 mg/day 
DHA: 1050 and 1290 mg/day 
NFSA requested VKM to assess the safety of “other substances” (in accordance to the 
guidance document developed in Phase 2) at the doses specified (Phase 3). 
Safety assessments for “other substances” present in food supplements shall be carried out 
for a general population, ages 10 years and above. 
  
  




“Other substances” are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional or physiological effect, and may be 
added to food supplements or e.g. energy drinks.  
This risk assessment regards the single substances eicosapentaenoic acid (EPA), 
docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) per se, and no specific 
products. 
VKM has in this series of risk assessments of “other substances” not evaluated any potential 
beneficial effects from these substances, but merely possible adverse effects at specified 
doses used in Norway. 
According to information from the Norwegian Food Safety Authority (NFSA), EPA, DPA and 
DHA are food supplement ingredients in Norway, and NFSA has requested a risk assessment 
of EPA in the following doses in food supplements: 1500, 1750 and 1825 mg/day; of DPA in 
the doses of 100, 125 and 150 mg/day and of DHA in the doses of 1050 and 1290 mg/day. 
EPA (20:5n-3), DPA (22:5n-3) and DHA (22:6n-3) are referred to as omega-3 or n-3 long 
chain polyunsaturated fatty acids (n-3 LCPUFAs), and are naturally found in fish and 
seafood. Mean intake of EPA, DPA and DHA from fish oil/ cod liver oil in adults participating 
in a nationally representative dietary survey was 735 mg/day, n=1787 (1982 mg/day in 
consumers only, n=663) (VKM, 2014). Concentrations of the n-3 LCPUFAS in cod liver oil 
may vary, and a recommended dose of 5 ml may contain 400 mg EPA, 60 mg DPA and 600 
mg DHA. 
The n-3 LCPUFAs are naturally bound to major lipid classes such as triacylglycerols (TAGs) or 
phospholipids (PLs). In food supplements these fatty acids can be bound to TAGs and PLs, 
but given as single fatty acids most formulations are as ethyl esters or as free fatty acids. 
EPA can be transformed to eicosanoids such as prostaglandins, prostacyclins and 
leukotrienes, all groups are biologically active substances. Eicosanoids participate in the 
regulation of blood pressure, renal function, blood coagulation, inflammatory and 
immunological reactions. DHA is an essential structural component of the brain, skin, sperm, 
testicles and retina. DPA can be retro-converted to EPA or converted to DHA. Still little is 
known of DPA’s specific biologic effects.  
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2 Hazard identification and 
characterisation 
2.1 Literature 
This risk assessment is based on previous risk assessments of EPA, DPA or DHA and articles 
retrieved from literature searches. 
 Previous risk assessments  2.1.1
Risks related to EPA, DPA and/or DHA have previously been evaluated by the Institute of 
Medicine, USA (IOM, 2005), VKM (2011)and the European Food Safety Authority (EFSA) with 
regard to food supplements (EFSA, 2012). 
Since these fatty acids are absorbed almost completely regardless of the source, i.e. free 
fatty acids, ethyl esters, phospholipids or triacylglycerols, the reports concluded that there 
was no need to undertake separate safety assessments for different sources of n-3 LCPUFA. 
Dietary reference intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, 
Cholesterol, Protein, and Amino Acids, USA 2005 
In the IOM report the potential hazards of EPA and DHA intake were identified. Concerns 
were given to immune function, bleeding and increased risk of haemorrhagic strokes and 
oxidative damage. In the IOM report twenty publications from 1985 to 2000 are referred to 
which show suppression of various immune function in vitro or ex vivo studies in different 
cell cultures from individuals provided EPA and DHA supplements or as experimental diets. 
IOM concluded that due to differences in study design it was not possible to draw any 
conclusions on the impact on immune functions of EPA and DHA supplementation. It was 
also mentioned that a few animal studies had shown effect of n-3 fatty acid supplementation 
on infection response (IOM, 2005), but in 2005 there was no data for support in humans. 
Twelve short-term studies (4 to 11 weeks) were reported to have found increased bleeding 
time, whereas three studies using similar intake found no impact of n-3 LCPUFAs 
supplementation. It was reported that there was a dose dependent increase in bleeding time 
of EPA and DHA supplementation, but that none of the studies reported excessive bleeding 
time, bleeding episodes or bruising. Ecological studies suggested an increased risk of 
haemorrhagic stroke among Greenland Eskimos with an average intake of 6.5 g/day of EPA 
and DHA. However, due to uncontrolled conditions these studies were not taken into 
consideration.  
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LCPUFAs are vulnerable to lipid peroxidation, but in studies with vitamin E supplementation 
in addition the oxidative damage was reduced or prevented. 
In addition, IOM described two subpopulations that should take supplements containing EPA 
and DHA with caution: those individuals who already exhibit glucose intolerance or diabetic 
conditions that require increased doses of hypoglycemic agents and individuals with familial 
hypercholesterolemia using anticoagulants. However, IOM considered the scientific data 
insufficient to establish an UL.  
VKM Evaluation of negative and positive health effects on n-3 fatty acids as 
constituents of food supplements and fortified foods, Norway 2011.  
The VKM report is an evaluation of negative and positive health effects of supplemental n-3 
fatty acid use (VKM, 2011). The evaluation of negative health effects was based on human 
studies retrieved in a literature search limited to the years 2000-2009. VKM concluded that 
no clear adverse effects from combined EPA and DHA up to the dosage 6.9 g/day were 
identified. An increased bleeding time had been found after intake of 6.9 g/day EPA and DHA 
in coronary heart disease patients on anti-thrombotic medication. However, no negative 
health effects regarding bleeding complications in connection with EPA and DHA 
supplementation had been reported. Possible negative health effects of combined EPA and 
DHA had been reported in various patient groups at doses above 3.5 g/day, including 
increases in biomarkers indicative of lipid peroxidation and endothelial cell activation. No 
tolerable upper intake level was established. No evaluation was done for EPA, DPA and DHA 
given as single fatty acids in food supplements.  
Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid 
(EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), EFSA 2012 
The mandate in the EFSA opinion was to establish a tolerable upper intake level (UL) for 
EPA, DPA or DHA individually or combined in the general population and vulnerable groups. 
If ULs could not be established EFSA was asked to provide advice on a daily intake of these 
fatty acids which does not give rise to concerns about adverse health effects either 
individually or combined. The EFSA opinion is based on data from human studies and the 
safety assessment of EPA, DHA and DPA referred to long-term consumption (EFSA, 2012). 
Since these fatty acids are absorbed almost completely regardless of the chemical forms, the 
EFSA Panel considered that there was no need to undertake separate safety assessments for 
this factor. EFSA concluded that long-term supplemental intakes of EPA and DHA combined 
up to about 5 g/day do not appear to increase the risk of spontaneous bleeding episodes or 
bleeding complications, or to affect glucose homeostasis, immune function or lipid 
peroxidation, provided the oxidative stability of the n-3 LCPUFAs is guaranteed. EFSA 
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concluded further that available data are not sufficient to establish a tolerable upper intake 
level for the n-3 LCPUFAs individually or in combination for any population group.  
A study by Clarke et al. (1990) reporting epistaxis episodes among 11 adolescents (11-21 
years old) who received up to 5 g/day of EPA and DHA was cited in the EFSA opinion. 
However, this was a non-randomised study with few participants and a later open labelled 
study in nine children (mean age 11.4 years) found no effects on bleeding after 8 weeks with 
an intake up to 16.2 g EPA/DHA per day (Sorgi et al., 2007). In 2012 the EFSA Panel omitted 
the results from the Clark study in their conclusions.  
It was concluded that supplemental intakes of 1.8 g/day of EPA did not raise safety concerns 
for adults based on bleeding complications, bleeding time and platelet function. No 
conclusions were made for infants, children and adolescents for EPA, and no conclusion was 
made for safe intake of DPA due to few studies and insufficient knowledge about biological 
mechanisms of this fatty acid. 
Supplemental intakes of 1 g/day of DHA alone do not raise safety concerns for the general 
population (including children and adolescent). No information was provided regarding how 
they reached their conclusion of up to 1 g DHA per day.  
 Literature search 2.1.2
A main literature search was performed in MEDLINE and EMBASE in order to retrieve 
publications on adverse effects caused by EPA, DPA or DHA after 2011. The latest previous 
report (EFSA) is from 2012, but we could not identify if EFSA had been able to include all 
studies from 2011, and we therefore included studies from 2011 in our search. This is 
probably an overlap of EFSA's search. The literature search was performed 30 April 2015. 
The strategy for the main search is included in Appendix 1. When writing the risk 
characterisation and conclusions for children and adolescents, it was considered that extra 
literature searches for children and adolescents were warranted as was a literature search 
for animal studies with DPA. These additional searches were performed 4 June 2015 
(specified for children and adolescents) and 16 June 2015 (including both human and animal 
studies with DPA).  
The strategies for these additional searches are also included in Appendix 1.  
The main search and the additional searches specified for children and adolescents were all 
limited back in time to include papers from the beginning of 2011, except for the additional 
search for animal studies with DPA which was unlimited back in time. 
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2.1.2.1 Publication selection 
The study types for inclusion in this opinion have been human studies. Animal studies were 
not included in the main literature search due to numerous human studies with EPA and 
DHA. The criteria for inclusion were: 
 EPA, DPA or DHA in relation to adverse effect must be addressed in the abstracts of 
the paper 
 Outcome not affected by other substances than EPA, DPA or DHA 
 Oral route of exposure to EPA, DPA or DHA in human studies 
 Human studies were performed in apparently healthy individuals or patient groups 
who are assumed to have normal EPA, DPA or DHA absorption and metabolism. 
In vitro studies were not included. Also papers in languages other than English, Norwegian, 
Danish or Swedish were excluded. The main literature search 30 April 2015 identified 252 
articles.  
The additional literature searches 4 June 2015 specified for children and adolescents 
identified 29 articles for EPA, 10 articles for DPA and 91 articles for DHA (several papers 
included in more than one search). 
The additional literature search for animal studies with DPA 16 June 2015 identified 82 
articles. Most studies reported on DPA n-6 and only one study concerning DPA n-3 has been 
included in this evaluation.  
Study titles and abstracts were first reviewed by the authors of this report, resulting in 
selection of 28 full text articles. After review of the available full text articles using the same 
inclusion criteria as above, 14 articles were included.  
A final total of 14 publications were identified and included in the results in this report (see 



























Figure 2.1.2.1-1: Flow chart for publication selection for EPA, DPA and DHA literature search. 
2.2 General information 
 Chemistry 2.2.1
The n-3 LCPUFA have their first double bond between carbon atoms number 3 and 4 from 
the methyl end, hence they are named n-3 or omega-3 fatty acids.  
EPA (20:5Δ4c,7c,10c,13c,16c) is an n-3 LCPUFA. The CAS number for EPA is 10417-94-4. 
Main search 
The publications were identified searching 
Medline and Embase 
Titles and abstracts 
n = 252 





1 human study in 
children and 1 animal 
study included 
Publications not fulfilling the inclusion 
criteria were excluded 
n = 14 
Publications not fulfilling the inclusion 
criteria were excluded 
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Figure 2.2.1-1: Structural formula for EPA. 
DPA (22:5Δ4c,7c,10c,13c,16c) The CAS number for DPA is 25182-74-5. 
 
Figure 2.2.1-2: Structural formula for DPA. 
DHA (22:6Δ4c,7c,10c,13c,16c,19c ) The CAS number for DHA is 6217-54-5. 
 
Figure 2.2.1-3: Structural formula for DHA. 
 Occurrence 2.2.2
Regular foods contain combinations of EPA, DPA and DHA, and food supplements or fortified 
foods are the only sources for isolated single EPA, DPA and DHA. The endogenous 
production of EPA, DPA and DHA from ALA is limited and insignificant compared to doses 
used in supplementation studies. 
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Main dietary sources of n-3 LCPUFAs are fatty fish, human milk, cod liver-, seal-, whale-, 
fish- and krill-oils. N-3 LCPUFA supplements are also produced from marine algae and fungi. 
2.3 Absorption, distribution, metabolism and excretion 
Alpha-linolenic acid (ALA, 18:3 n-3) is the essential n-3 fatty acid which is found in seeds 
(chia, flaxseed), nuts (notably walnuts), and in many common vegetable oils. ALA is the 
precursor for EPA, DPA and DHA. However, humans have a limited capacity for endogenous 
production of the n-3 LCPUFAs because ALA competes with linoleic acid (LA, 18:2 n-6) for 
the same enzyme system of elongases and desaturases for the endogenous production of 
arachidonic acid (AA, 20:4 n-6). In a western diet, the LA:ALA ratio varies between 5-9, 
which favors the production of AA. Analyses with radioisotope labelled ALA suggest that less 
than 10% of ALA is converted to EPA and further 0.1 to 9% to DHA (Williams and Burdge, 
2006). The conversion of ALA to EPA is further dependent on gender and is more limited in 
men compared with women, possibly due to the regulatory effects of estrogen (Burdge, 
2004). 
The intakes of EPA, DPA and DHA from regular foods are in the form of triacylglycerol (TAG) 
and phospholipids (PLs). In food supplements these fatty acids can be bound to TAGs and 
PLs, but given as single fatty acids most formulations are as ethyl esters or as free fatty 
acids. According to EFSA (2012), EPA, DPA and DHA are absorbed almost completely 
regardless of the source. New studies show that the bioavailability of the n-3 LCPUFAs as 
free fatty acids is higher in comparison with ethyl esters (Maki et al., 2013; Offman et al., 
2013).  
In the intestine TAG, PLs and ethyl esters undergo lipolysis by different lipases and the n-3 
LCPUFAs are absorbed into the enterocytes. This step does not apply to the free fatty acids. 
The enterocytes incorporate the n-3 LCPUFA into TAGs or PLs which together with 
cholesterol, cholesterol esters and apo-lipoproteins are assembled into chylomicrons that 
enter the circulation via the lymphatic system. Circulating chylomicrons release the n-3 
LCPUFAs to adipose tissue and other tissues and organs.  
In the liver, EPA, DPA and DHA are together with other fatty acids (both exogenous and 
endogenous) incorporated into very low-density lipoprotein (VLDL) particles which enter 
directly to the venous blood circulation. Circulating VLDL releases these fatty acids to various 
tissues and organs before the remaining low-density lipoprotein (LDL) is taken up by the 
liver through LDL receptors. However, in the event that the LDL particle becomes oxidised 
(oxLDL) it is taken up by macrophages, which ultimately leads to formation of foam cells and 
the formation of fatty streaks that is the initial step in atherosclerosis (Lusis, 2000).  
EPA is incorporated into cell membranes and may thus impact cellular metabolism, signal 
transduction and regulation of gene expression. EPA can be transformed to eicosanoids, a 
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group of biologically active substances including prostaglandins, prostacyclin and 
leukotrienes, which participate in the regulation of blood pressure, renal function, blood 
coagulation, inflammatory and immunological reactions and other functions in tissues. EPA is 
also the precursor for the 5 series of leukotrienes. In addition, both EPA and DHA are 
metabolised to specialised pro-resolving lipid mediators like resolvins, poxytrins, 
neuroprotectins and maresins, which are thought to be involved in resolution of 
inflammatory responses (Chen et al., 2011; Dobson et al., 2013; Serhan et al., 2008; Spite 
et al., 2014).  
DHA is a structural component of cell membranes and contributes to various membrane 
functions such as fluidity, permeability, activity of membrane-bound enzymes and receptors, 
and signal transduction in nervous tissue and retina. DHA is not a substrate for mitochondrial 
beta-oxidation, i.e. energy production (energy as adenosine triphosphate (ATP)), but DHA 
can be beta-oxidised by peroxisomes (yielding energy as heat). In addition, DHA is 
metabolised to F4-neuroprostanes and endocannabinoids. 
DPA can be retro-converted to EPA and only minimally to DHA (EFSA, 2012). More recently, 
it was shown that interconvertion of DPA to EPA and DHA was very limited and there was no 
increase in EPA levels after a 5 hour postprandial period following a breakfast supplemented 
with 2 g DPA (Linderborg et al., 2013). 
Few studies have investigated the biologic effects of DPA alone, but it is suggested that DPA 
may affect membrane structure differently from EPA and DHA and thereby have independent 
effects on enzyme activity and gene expression. DPA might inhibit platelet aggregation and 
stimulate endothelial cell migration more efficiently than both EPA and DHA (Kaur et al., 
2011; VKM, 2011; Yazdi, 2013). Supplementation with 8 g of either pure DPA or EPA 
resulted in different and specific incorporation patterns into plasma lipid classes and red 
blood cell PLs (Miller et al., 2013).  
2.4 Adverse effects noted in previous reports 
Adverse effects of high intakes of n-3 LCPUFA are described as bleeding episodes, impaired 
immune function, increased lipid peroxidation, and impaired lipid and glucose metabolism 
(EFSA, 2012; VKM, 2011). Most studies have been performed with food supplements 
containing EPA and DHA in combination and as TAG. Few studies refer to single fatty acid 
supplementation.  
 Bleeding complications and bleeding time 2.4.1
Increased tendency to bleed from the nose and urinary tract, and increased mortality from 
haemorrahagic stroke have been reported in observational studies of Greenlandic Eskimos 
  
VKM Report 2015: 27  26 
 
(mean intakes of n-3 LCPUFAs about 6.5 g/day) as well as prolonged bleeding time and 
reduced platelet aggregation (Dyerberg and Bang, 1979). These studies were uncontrolled 
for factors other than the intake of n-3 LCPUFA.  
Bleeding complications were studied in an open label human intervention study (Yokoyama 
et al., 2007) cited in VKM (2011) and EFSA (2012), which investigated the effects of 
1.8 g/day of EPA as ethyl esters consumed for five years in combination with statins 
(n=9326) vs. statins alone (n=9319) in hypercholesterolemic, high fish consumers on 
primary and secondary prevention of coronary heart disease. In this study adverse outcomes 
were assessed and published in a separate paper (Tanaka et al., 2008) cited in EFSA 2012. 
Bleeding (cerebral and fundal bleedings, epistaxis, and subcutaneous bleeding combined) 
was more frequently reported in the EPA group than in controls. EFSA (2012) noted that 
nose- or subcutaneous bleeding was self-reported, and that self-reported side effects are 
subject to high reporting bias in open label studies. EFSA further noted that no statistically 
significant differences in the total incidence of stroke, or in the incidence of cerebral or 
subarachnoid haemorrhage, were observed between groups. EFSA considered that an intake 
of EPA alone at doses up to 1.8 g/day for five years does not increase the risk of bleeding 
complications. 
The aim of a review article from 2014 was to look at the effects of n-3 fatty acids on 
bleeding complications in a variety of clinical settings and in combinations with different anti-
platelet drugs or anticoagulant therapies (Wachira et al., 2014). It was stated that although 
platelets are affected by n-3 fatty acids supplementation, impact on bleeding time and 
bleeding complications is minor. New insights indicate that fish oil can somewhat lower 
platelet arachidonic acid levels and possibly slightly diminish the cyclooxygenase (COX)-
derived signalling cascade. Besides COX, n-3 fatty acids are substrates for several enzymes 
that produce active metabolites which can affect platelets function.  
Neither in the present nor in the EFSA opinion, were any studies with single DPA or DHA 
supplementation investigating bleeding complications or bleeding time identified.  
 Immune function 2.4.2
According to the EFSA opinion from 2012, there are no human intervention studies available 
that have investigated the effects of n-3 LCPUFA supplementation on the risk of infections 
(EFSA, 2012).  
There are some indications, from ex vivo and in vitro studies performed in peripheral blood 
white cells of human subjects consuming n-3 LCPUFA, that EPA and DHA may decrease the 
expression of cytokines and the proliferation of peripheral white blood cells at doses as low 
as 0.9 g/day EPA and 0.6 g/day DHA consumed as fish oil for 6-8 weeks as reviewed in IoM, 
2005. However, the clinical relevance of these changes is unknown.  
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Furthermore, there is no available information on the effect of a high intake of n-3 LCPUFA 
on the risk of chronic diseases with an inflammatory component. Some markers of the so-
called low-grade systemic inflammation (e.g. high-sensitivity C-reactive protein, and some 
cytokines) and vascular (e.g., sICAM-1, VCAM-1, and E-selectin) have been associated with 
an increased risk of cardiovascular events in healthy and high-risk subjects. However, there 
is no evidence that changes induced by diet or drugs in any of these markers modify the risk 
of disease per se. Most of the intervention studies available that report on the effects of EPA 
and DHA on markers of systemic and vascular inflammation are small and generally not 
designed for the purpose. Although an increase in E-selectin and/or in sVCAM-1 has been 
reported in some studies at doses of EPA and DHA of about 5 g/day, a recent meta-analysis 
of 18 randomised controlled trials found no effect of n-3 LCPUFA supplementation (dose 
0.272 to 6.6 g/day) on these markers of vascular inflammation nor a significant decrease in 
sICAM-1 (Yang et al., 2012) included in EFSA 2012). The majority of the studies report either 
no effect or a decrease in systemic markers of inflammation, including hs-CRP (high-
sensitivity C-reactive protein) and TNF-alpha (Bloomer et al., 2009; VKM, 2011).  
EFSA (2012) noted that the data available are insufficient to conclude on whether the same 
doses administered mostly as EPA or mostly as DHA would have different effects on this 
outcome. 
 Peroxidation 2.4.3
PUFAs are generally more prone to peroxidation compared with saturated fatty acids. 
Enhanced oxidative stress and increased lipid peroxidation either locally in the vessel wall or 
systemically have been associated with the pathogenesis of atherosclerosis in humans and 
the relation to adverse effects (IOM, 2005; Steinberg et al., 1989; VKM, 2011).  
The majority of the human intervention studies used fish oils stabilised with antioxidants, but 
some studies did not report whether sources of EPA, DHA, or both, contained antioxidants. 
Only a few studies reported on the concentration of primary and secondary oxidation 
products in the supplements administered. The addition of antioxidants to food supplements 
containing n-3 LCPUFA to ensure product stability appears to be optional (EFSA, 2012). 
F2-isoprostanes measured in urine or plasma are reliable markers of in vivo lipid 
peroxidation. In 2011, VKM identified nine controlled human intervention studies that used 
n-3 LCPUFA-rich oils stabilised with antioxidants, mostly with vegetable oils as control (olive, 
maize, sunflower, safflower or soy oil), and reported on plasma or urinary F2-isoprostanes 
(VKM, 2011). Studies were conducted in newborns (following maternal supplementation with 
4 g/day EPA and DHA from fish oil from 20 weeks of gestation until delivery) (Barden et al., 
2004), pre-term infants (EPA and DHA were incorporated to the pre-term formula; 5.25-
8.75 mg/100 mL of formula) (Stier et al., 2001) or children/adolescents with familial 
hypercholesterolaemia (9-19 years, 1.2 g/day DHA) (Engler et al., 2004). The remaining 
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studies had recruited a variety of adults who were either healthy (e.g. young men, post-
menopausal women) or with various disease conditions (e.g. obesity, non-insulin-dependent 
diabetes mellitus, hypertension, end-stage renal disease), and used either DHA alone (0.8-
4 g/day), EPA alone (1.6-4 g/day) or EPA and DHA in combination as fish oil (2-4 g/day) for 
three to six weeks. The studies of longer duration (six weeks) used the highest doses of EPA 
and DHA, both alone and in combination. Half of the studies reported a significant decrease 
in plasma or urinary concentrations of F2-isoprostanes in the n-3 LCPUFA group compared 
with the controls (Barden et al., 2004; Higdon et al., 2000; Mas et al., 2010; Mori et al., 
2000; Mori et al., 2003), whereas the remaining studies did not observe significant changes 
between groups (Engler et al., 2004; Himmelfarb et al., 2007; Stier et al., 2001; Tholstrup et 
al., 2004; Wu et al., 2006).  
Susceptibility of LDL to oxidation has in a number of studies been reported to be increased, 
decreased or unchanged during consumption of EPA and DHA either from fish oil or as ethyl 
esters. Whereas an increased susceptibility of LDL to oxidation has been reported in some 
short-term studies (4-6 weeks), longer-term interventions (6-16 weeks) showed no effect (of 
EPA and DHA) in comparison with control (mostly vegetable oils) at doses up to about 
5 g/day (VKM, 2011). In two studies in which the diet was supplemented with salmon 
providing EPA + DHA, 1.5 g/day or 2.9 g/day (Seierstad et al., 2005) or herring providing 
EPA + DHA, 1.2 g/day (Lindqvist et al., 2009) the intervention had no effect of on plasma 
oxidised LDL concentrations in comparison with controls (EFSA, 2012).  
EFSA concluded that intakes of EPA and DHA consumed alone or in combination at doses up 
to 4 g/day for six weeks do not induce lipid peroxidation as assessed by F2-isoprostanes. 
 Impaired lipid and glucose homeostasis 2.4.4
From intervention studies, mostly uncontrolled, adverse effects on lipid- and glucose 
metabolism from supplemental intake of n-3 LCPUFA (≥10g/day) have been described. EFSA 
concluded that an intake of EPA and DHA combined up to 5 g/day consumed for 12 weeks 
does not significantly affect glucose homeostasis in healthy or diabetic subjects, but that 
scientific data is not available to conclude whether the same doses administered as EPA or 
DHA alone would have a different effect.  
Several human studies have addressed the effects of supplementation with n-3 LCPUFA on 
blood LDL-cholesterol concentrations. EFSA (2012) concluded that 2-6 g/day of supplemental 
EPA and DHA combined or 2-4 g/day of mostly DHA, increases the blood concentration of 
LDL-cholesterol by about 3% and that such an increase is accompanied by a decrease in 
TAG with no changes in HDL-cholesterol concentrations. Supplementation of mostly EPA had 
no such effect on cholesterol concentrations. The small increase in LDL-cholesterol by 
EPA+DHA supplementation or DHA supplementation alone was not considered as an adverse 
effect by the EFSA Panel.  
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2.5 Human studies published after 2010 
Fourteen human studies included from our literature searches are listed in the table below. 
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 Randomised controlled trials (RCTs) 2.5.1
A double-blind, randomized controlled clinical trial comparing eicosapentaenoic 
acid versus docosahexaenoic acid for depression, Mischoulon et al. 2015 
196 adults (53% female; mean age 44.7 years) with major depressive disorder (MDD) were 
randomised to 8 weeks intervention with oral EPA or DHA enriched n-3 preparations as 
monotherapy 1 g/day or placebo (Mischoulon et al., 2015). Adverse effects were measured 
using the Patient-Rated Inventory of Side Effects (PRISE). Because many subjects endorsed 
PRISE symptoms at baseline, the analysis focused on adverse effects that emerged or 
worsened during treatment. Self-reported safety data were available for 173 subjects. No 
significant differences across treatment groups were observed. Of the 21 physical symptoms 
assessed, only two were significantly different between treatment groups (constipation: 
13.3% for EPA-enriched, 14.3% for DHA-enriched, and 0.0% for placebo; P=0.010; and 
tremors: 1.7% for EPA-enriched, 8.9% for DHA-enriched, and 0% for placebo; P=0.020. One 
EPA-enriched group subject discontinued due to worsening depression, and one placebo 
patient discontinued due to an unspecified “negative reaction to pills”. The authors 
concluded that both n-3 preparations were well tolerated. 
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Safety assessment of docosahexaenoic acid in X-linked retinitis pigmentosa: The 
4-year DHAX trial, Hughbanks-Wheaton et al. 2014. 
Males (n=78; 7-31 years with retinitis pigmentosa were randomised to receive 30 mg 
DHA/kg bw (n=33) or to placebo = corn/soy oil (n=27) for at least 1 year, but was 
continued for 4 years and the principle of intention to treat was applied (Hughbanks-
Wheaton et al., 2014). All related or unrelated possible adverse events, both self-reported 
and through blood analyses, were recorded but only treatment related adverse events were 
evaluated. Thirteen compared to 6 possible treatment related adverse events were seen in 
the DHA treated group compared to placebo group and mostly gastrointestinal discomfort, 
but also dehydration (2 cases), increased sensitivity to allergens (1 case), hypothyroidism (1 
case), and hypercholesterolemia (1 case) was reported. Of the blood parameters only 7 
adverse events were seen in the DHA treated group compared to 13 in the placebo group. 
The authors concluded that the adverse events were minor and sporadic in occurrence and 
duration and no significant difference was seen in antioxidant activity or oxidised LDL. Mean 
fasting glucose levels were marginally reduced after the 4-year DHA intervention, but was 
not significantly different compared to placebo (P= 0.08). No significantly altered lipoprotein 
cholesterol or TAG levels were observed in this trial. 
Effects of pure eicosapentaenoic and docosahexaenoic acids on oxidative stress, 
inflammation and body fat mass in patients with type 2 diabetes, Azizi-Soleiman 
et al. 2013 
Sixty patients with type 2 diabetes were randomly allocated to receive daily either ~1 g EPA 
or ~1 g DHA, or canola oil as placebo for 12 weeks in a randomised triple-blind, placebo-
controlled trial (Azizi-Soleiman et al., 2013). With regard to side effects withdrawals from the 
study were due to swallowing four capsules per day and intestinal side effects in EPA and 
DHA groups, and personal reasons in the placebo group. However, no figures were given for 
withdrawal. The main findings of this trial were that both EPA and DHA did not significantly 
affect oxidative stress, inflammation, blood lipids, body weight or fat mass in patients with 
type 2 diabetes as compared to placebo. 
Postprandial metabolism of docosapentaenoic acid (DPA, 22:5n-3) and 
eicosapentaenoic acid (EPA, 20:5n-3) in humans, Linderborg et al. 2013 
Ten healthy, normal weight women between the age of 20 and 30 years participated in this 
randomised cross over study with three different supplements included in a standard 
breakfast meal (Linderborg et al., 2013). The standard breakfast contained 18 g of olive oil. 
Each period lasted three days with the standard breakfast and on the third day either 2 g of 
olive oil, or 2 g of DPA or 2 g of EPA was included in the breakfast. Blood was drawn each 
hour for 5 hours after intake of the DPA, EPA or olive oil rich breakfast. Each test period was 
followed by a 2-week wash-out period. During the study the participants were asked to 
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refrain from intake of fatty fish or other supplements containing fatty acids. This study, 
designed to test if dietary DPA was significantly less absorbed than EPA, showed that plasma 
TAGs remained at fasting level after the DPA breakfast and a significantly lower 
concentration of chylomicrones was seen 1 to 3 hours after the DPA rich meal. A reduced 
incorporation of DPA compared with EPA into chylomicrons was seen 5 hours after the 
meals. The authors suggested that one possible mechanism explaining the DPA induced 
chylomicronemia could be that DPA acted as a pancreatic lipase inhibitor. This hypothesis 
was supported by the recorded observation that three out of the ten subjects reported 
diarrhea or upset stomach 3 hours after the DPA breakfast. Another explanation suggested 
by the authors was that the TAGs could be stored in the enterocytes and released over a 
longer time span than the 5 hours. Furthermore, there was negligible conversion of DPA and 
EPA to DHA. Further studies are required on the effect of pure DPA since DPA seems to be 
differently metabolised and causes an effect different from that of EPA and DHA (Linderborg 
et al., 2013). No safety evaluations were performed in this study. 
Docosahexaenoic acid supplementation, vascular function and risk factors for 
cardiovascular disease: A randomised controlled trial in young adults, Singhal et 
al. 2013 
Healthy volunteers (n=328), aged 18 to 37 years, were randomly assigned to 1.6 g DHA/day 
(from a microalgae source) together with 2.4 g/day carrier oil (index group) or to 4.0 g/day 
olive oil (control) (both given in eight 500-mg capsules/day for 16 weeks) (Singhal et al., 
2013). Flow-mediated endothelium-dependent vasodilation of the brachial artery (primary 
outcome) was measured before and after the intervention (n=268) using high-resolution 
vascular ultrasound. Data on adverse effects and tolerance were recorded for the preceding 
7 days during monthly phone calls. There were no serious adverse events in either dietary 
group and both diets were well tolerated. No participant dropped out of the study due to 
adverse effects associated with either dietary supplement (the most common reason for 
dropping out was social). Tolerance data were obtained in 133 and 129 participants from 
control and DHA-supplemented groups, respectively. Most study participants did not 
experience any adverse events (86/133 and 84/129 in control and DHA-supplemented 
groups, respectively). The most common problems were gastrointestinal, but the incidence 
of these was similar in both randomised groups (23% [n=31/133] and 25% [n=32/129] in 
control and DHA-supplemented groups, respectively) (for specific symptoms in control and 
DHA-supplemented groups, respectively: abdominal pain, n=3 and 5; nausea, n=2 and 5; 
bloating, n=6 and 7; flatulence, n=12 and 9; diarrhea, n=4 and 4; and constipation, n=4 
and 2). There was no effect on fasting concentrations of insulin, glucose, or CRP. Fasting 
concentrations of VLDL and TAG were lower in the DHA-supplemented compared with the 
control group. 
DHA supplementation improved both memory and reaction time in healthy young 
adults: a randomized controlled trial, Stonehouse et al. 2013 
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Healthy adults (n=176); age range 18-45 years; non-smoking and with a low intake of DHA 
completed a 6 month randomised, placebo-controlled, double-blinded intervention with 
1.16 g DHA/day or a placebo (Stonehouse et al., 2013). At the end of the study, each 
participant completed a computer-based tolerance questionnaire that included side effects 
such as dizziness, diarrhea, nausea, burping, heartburn/reflux, unpleasant breath/bad taste 
and feeling tired. With regard to side effects, a significantly greater proportion of participants 
in the DHA-treatment group reported burping and unpleasant breath [burping: 49% 
compared with 22%, respectively (P<0.001); unpleasant breath: 39% compared with 18%, 
respectively (P<0.001)], but the adverse effects were rated as minor (1 and 2 on a scale 
from 1 to 10). No data on blood lipids, glucose or insulin levels were given and no serious 
adverse effects were reported. 
Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese 
subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-
3 fatty acid randomized double-blind (ORD) study, Tatsuno et al. 2013 
In this randomised, double-blind study subjects with hypertriglyceridemia was investigated 
(Tatsuno et al., 2013). One group was given 2 g of TAK-085 once daily (n=205), one group 
got 2 g of TAK-085 twice daily (n=210) and one group was given EPA as ethyl ester 0.6 g 
three times daily (n=195) for 12 weeks. One gram of TAK-085 contains a combination of 
concentrated EPA (465 mg) and DHA (375 mg), mostly as ethyl esters. Safety was monitored 
via the occurrence of adverse advents and changes in clinical laboratory tests (haematology, 
serum chemistry and urine analysis) at each visit (weeks 0, 4, 8, 10 and 12). There were no 
significant difference in adverse events between the three groups and there were no 
apparent relation with the dose of TAK-085. There were no clinically relevant changes in 
haematology, serum chemistry, urine analysis or vital signs. All three treatments were well 
tolerated, but no control group was included. 
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in 
statin-treated patients with persistent high triglycerides (from the Anchor study) 
Ballantyne et al. 2012 
This is multicenter, placebo-controlled, randomised, double-blinded 12-week clinical study in 
high-risk, statin treated patients with hypertriglyceridemia (TAG levels ≥ 200 and 
<500 mg/dl).One group was given 4 g AMR101/day (n=233), second group got 2 g 
AMR101/day (n=236) and the third group got placebo (paraffin) (n=233) (Ballantyne et al., 
2012). AMR101 contains 96% EPA as ethyl ester, equaling 3.8 g and 1.9 g of pure EPA as 
ethyl ester. Adverse events were self-reported and CRP was determined. Adverse events 
were mild or moderate in severity and considered unrelated to study drug. Diarrhea, nausea, 
nasopharyngitis and arthralgia occurred in 3% of the patients. Only arthralgia occurred in a 
larger percentage of patients treated with AMR101 versus placebo, but was highest in the 
group treated with 2 g of AMR101/day of EPA (no dose effect). The most common treatment 
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related adverse events were gastrointestinal disorders, which occurred in a larger percentage 
of patients in the placebo group. Eructations were reported by 2, 1, and 4 patients receiving 
4 g, 2 g AMR101 daily or placebo, respectively. 
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high 
triglyceride levels (from the multi-centre, placebo-controlled, randomised, 
double-blind, 12-week study with an open-label extension [MARINA] trial), Bays 
et al. 2011 
This is another multicenter, placebo-controlled, randomised, double-blinded 12-week clinical 
study in patients with hypertriglyceridemia (TAG levels≥500 and <2000 mg/dl) (Bays et al., 
2011). One group was given 4 g AMR101/day (n=77), second group got 2 g AMR101/day 
(n=76) and the third group got placebo (paraffin) (n=76). AMR101 contains 96% EPA as 
ethyl ester. In this study not all patients were on statin treatment. The safety evaluation was 
done using reported adverse events, clinical laboratory assessments, 12-lead 
electrocardiographic findings, physical examination findings, weight and body mass index 
and vital signs like heart rate and blood pressure. Adverse events were recorded by the 
investigator (who was unaware of the treatment regimen) as related or not related to the 
study drug. Treatment-related adverse events were defined as those adverse events that 
had newly occurred or had worsened in severity during the double-blind treatment period. 
Most treatment related adverse events were mild to moderate in severity. About 35% of the 
patients reported treatment-related adverse events in all three groups. Most common were 
diarrhea, nausea and eructation, but these were more common in the placebo treated group. 
Changes in fasting plasma glucose and hemoglobin A1c (HbA1c) concentrations did not differ 
significantly that of the placebo group. Neither did the treatment with AMR101 at any dose 
change vital signs, electrocardiographic parameters, alanine aminotransferase, aspartate 
aminotransferase or creatine kinase values (Bays et al., 2011).  
Algal Docosahexaenoic acid affects plasma lipoprotein particle size distribution in 
overweight and obese adults, Neff et al. 2011 
Enrolled participants were between the ages of 18 and 65 years, healthy and obese, with a 
BMI of 30.0–39.9 kg/m2, or overweight, with a BMI of 25.0–29.9 kg/m2 and a waist 
circumference ≥ 102 cm in men or ≥ 88 cm in women (Neff et al., 2011). Thirteen 
individuals did not complete the study due to withdrawal of consent, unrelated adverse 
events, or noncompliance with the study protocol, and their data were excluded from the 
data analyses. The authors stated that DHA supplementation was well tolerated without 
significant side effects. Total cholesterol increased more with DHA than with placebo (P = 
0.031). There were no significant between-group differences in changes in TG, VLDL 
cholesterol, LDL cholesterol, or HDL cholesterol in response to treatment. However, in 
paired-sample analyses, TG levels decreased over time in the DHA group (P = 0.001) but not 
the placebo group (P = 0.15). In the DHA group, mean TG level decreased by 21% with 
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treatment. Nuclear magnetic resonance (NMR)-based calculations suggested that the DHA 
group had greater decreases in both total TG (P = 0.006) and VLDL TG (P = 0.009) than the 
placebo group. Treatment-associated changes in calculated HDL cholesterol level did not 
differ between the DHA and placebo groups (P = 0.53). No significant differences were 
detected between the DHA and placebo groups in changes in fasting glucose or insulin 
levels, HOMA-IR score, HbA1c, or the area under the curve for glucose or insulin during the 
oral glucose tolerance test. Changes in 24-hours monitored systolic and diastolic blood 
pressures over the course of the study did not differ significantly between the DHA and 
placebo groups. Compared with placebo, DHA had no significant effect on clotting 
parameters, including prothrombin time, activated partial thromboplastin time, and 
fibrinogen (data not shown). Markers of inflammation that were assessed in all participants 
included IL-1b, IL-6, IL-10, TNFα, lipopolysaccharidebinding protein, and CRP. Of these, the 
only significant between-group difference in change was a greater increase in plasma 
concentration of IL-10 (P = 0.021) after treatment in the DHA group than in the placebo 
group (Neff et al., 2011). 
Effects of Docosahexaenoic acid supplementation on blood pressure, heart rate, 
and serum lipids in Scottish men with hypertension and hypercholesterolemia, 
Sagara et al. 2011 
The study was a randomised double-blind placebo-controlled trial involving 156 males aged 
45–59 years. The study was conducted in two separate stages (Sagara et al., 2011). Stage 1 
was a screening survey for high-risk subjects for developing cardiovascular disease, included 
a structured questionnaire to obtain information about demographic characteristics, medical 
history and medication, and a clinical evaluation of height and weight, blood pressure, heart 
rate, and fasting blood lipid profile. Stage 2 was a five-week dietary supplementation period. 
Among the 56 high risk subjects 25 and 31 participants were assigned to the DHA group and 
to the active placebo group, respectively, randomly in a double-blind fashion. In the DHA 
group, DHA powder containing calcium encapsulated DHA (2 g/day) mixed in bread rolls 
were consumed in addition to the usual diet. The active placebo group received bread rolls 
containing calcium encapsulated olive oil powder (1 g/day). During each visit, dietary 
counselling, adverse events, compliance assessments, and any medication changes were 
documented. Participants completed a one-page questionnaire intended to identify any 
adverse effects of the supplements and they were asked to return the food record forms. 
The authors reported no adverse events. There was a significant reduction in mean systolic 
blood pressure (P < 0.001), diastolic blood pressure (P < 0.01), and heart rate (P < 0.05) in 
DHA supplemented group but not in the placebo group. The analysis of serum lipid profiles 
showed an increase in HDL-cholesterol and decrease in total cholesterol and non-HDL-
cholesterol/HDL-cholesterol ratios both in the placebo and DHA groups. There was no 
significant change in the total cholesterol and non-HDL-cholesterol during the 5 weeks of 
intervention in either group (Sagara et al., 2011). 
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 Other human studies 2.5.2
Eicosapentaenoic acid and docosahexaenoic acid in whole blood are differentially 
and sex-specifically associated with cardiometabolic risk makers in 8-11 year old 
Danish children, Damsgaard et al. 2014 
This is a cross sectional study performed in 713 children aged 8-11 years. One of the aims 
was to investigate associations between n-3 LCPUFA status measured as EPA and DHA in 
whole blood, and early cardiometabolic risk factors (Damsgaard et al., 2014). The study is a 
part of the OPUS project (Optimal well-being, development and health for Danish children 
through a healthy New Nordic Diet). In this study a negative association was found between 
whole blood EPA and TAG, and a positive association between EPA and cholesterol as well as 
a sex specific association with increased blood pressure in boys. Both EPA and DHA were 
negatively associated with heart rate and DHA with insulin resistance. Blood pressure was 
measured only at one occasion and just before blood sampling which was an important 
limitation of the study. However, the authors referred to a pilot study where DHA 
concentration in whole blood was associated with increased blood pressure among 8-11 year 
olds and in 7 year-old offsprings of mothers who received fish oil versus olive oil 
supplementation in pregnancy. 
Effects of Eicosapentaenoic Acid on Platelet Function in Patients Taking Long-
Term Aspirine Following Coronary Stent Implantation, Takada et al. 2014 
In this open labelled trial, 18 men (age 50-75 years) on stable medication (100 mg 
acetylsalicylic acid/day and stable statin treatment) who had undergone coronary stent 
implantation at least 8 months earlier, were given 1.8 g/day of EPA ethyl ester for 12 weeks. 
EPA was given in capsules (2 x 0.9 g) daily with meals (Takada et al., 2014). The main 
outcome of this study was the effect of EPA on platelet aggregation and platelet activation in 
patients under aspirin treatment after coronary stent implantation. In the group with the 
highest EPA/arachidonic acid (AA) ratio after treatment (n=10), there was a significant 
suppressed collagen-induced maximum platelet aggregation, but there were no change in 
normal platelet aggregation. In the patients with low EPA/AA ratio after treatment there 
were no changes in platelet aggregation.  
Effect of eicosapentaenoic acid agent on aggravated hypertriglyceridemia during 
pregnancy, Sato et al. 2013 
This study is a case report of a 29 year old multiparous pregnant women who was 
transferred to a hospital in week 29 + 0 of gestation due to hypertriglyceridemia (TAG = 
898 mg/dl) (Sato et al., 2013). She was treated with 1.8 g EPA/day and TAG concentration 
was reduced to 550 mg/dl. At week 37 + 2 of gestation she gave birth to a 2667 g baby who 
was borne with respiratory distress syndrome. After one week treatment, all symptoms of 
  
VKM Report 2015: 27  38 
 
respiratory problems were resolved. The authors concluded that treatment with EPA in 
patients with hypertriglyceridemia in pregnancy is a possible therapeutic approach although 
it might increase the risk of foetal respiratory distress syndrome.  
2.5.2.1 Interactions 
There was no information concerning interactions between any of the single fatty acids and 
other nutrients, drugs or any substance in the literature reviewed in the present risk 
assessment.  
2.5.2.2 Allergic sensitisation and adjuvant effects  
In one study increased sensitivity to allergens was reported after 4 years with 30 mg/kg bw 
DHA supplementation (Hughbanks-Wheaton et al., 2014). No other study reported 
information concerning allergic sensitisations and/or adjuvant effects of EPA, DPA or DHA in 
humans. 
 Animal studies 2.5.3
One animal study investigating DPA as single fatty acid was identified in the additional 
literature search (see section 2.1.2). Fard et al. (2014) conducted an animal study to 
examine the results for DPA from a human study, and to test whether DPA was metabolised 
differently than EPA. The rats were randomly divided into four groups and the first group 
was sacrificed at day 0. The rats were then fed a special diet with no EPA, DHA or DPA for 9 
days and on days 5, 6 and 8 the rats were feed either 250 mg/day of EPA or DPA as free 
fatty acids or olive oil. There was no statistically significant difference in the total amount of 
faecal fat between the three groups over the 9 day study, but faecal DPA excretion was 4.6 
–fold higher compared with EPA excretion. There was no significant difference in the content 
of DPA and DHA in plasma fatty acids at day 9, but the concentration of EPA was 
significantly higher in the groups fed DPA and EPA. It was also found that liver DPA, EPA and 
total amount of n-3 LCPUFA levels were significantly increased by DPA and EPA feeding 
compared with olive oil fed controls. In the heart, DPA feeding increased the DPA content 
and both DPA and EPA feeding increased the total n-3 LCPUFA level. The authors concluded 
that the DPA and EPA are metabolised differently, confirming the results from their human 
study (Linderborg et al., 2013). 
 Mode of action for adverse effects  2.5.4
Possible adverse effects of EPA, DPA and DHA include prolonged bleeding time, suppression 
of immune reactions, oxidation of LDL particles or lipoproteins and impact on lipid and 
glucose homeostasis in patients with type 2 diabetes (EFSA, 2012; IOM, 2005; VKM, 2011). 
  
VKM Report 2015: 27  39 
 
EPA and DHA are incorporated into phospholipids of all cell membranes. EPA and DHA are 
incorporated in the sn-2 position of phospholipids and thereby replacing other unsaturated 
fatty acids of the n-6 family such as arachidonic acid (AA). This may alter the fluid 
characteristics of the membranes, effecting changes in protein/enzyme function and ion 
channel conductance. The enzyme phospholipase A2 (PLA2) liberates EPA and DHA from the 
membrane into the cytoplasm, where they are subject to one of two oxidation pathways, the 
enzymatic or the non-enzymatic pathway.  
In the enzymatic pathway, n-6 and n-3 LCPUFAs are metabolised to eicosanoids, which can 
enter the nucleus where they down regulate expression of genes that promote inflammation. 
Eicosanoids act locally and they can also travel through the bloodstream where the n-3 
derived eicosanoids reduce platelet aggregation and the accumulation of fatty acids in the 
arteries. N-3 LCPUFAs are also subject to spontaneous oxidation by reactive oxygen species, 
which can attack EPA and DHA, both when free and when incorporated in membranes. 
These reactions result in the formation of lipid peroxides, such as hydroperoxy-DHA and -
EPA, which can activate transcription factors such as peroxisome proliferator-activated 
receptors (PPARs) and nuclear factor erythroid-derived 2 and up-regulate gene expression in 
the nucleus (Serhan et al., 2008; Spite et al., 2014).  
EPA 
EPA is known to influence platelet function. Platelet aggregation is mediated through the 
production of eicosanoids, especially thromboxane A2 (TXA2) and prostaglandin A2 (PGI2) 
from arachidonic acid. Upon platelet activation cell membrane fatty acid availability is of 
importance. If intake of n-3 fatty acids is high and the ratio of n-3 to n-6 fatty acids is 
increased the production will shift from TXA2 and PGI2production from arachidonic acid to 
production of TXA3 and PGI3 from EPA. TXA3 and PGI3 have local vasodilitatory and 
antiplatelet activating effects and reduce the production of platelet activating factor thereby 
increasing bleeding time. 
The production of the less proinflammatory eicosanoids participating in the regulation of 
inflammatory and immunological reactions might be positive for reduction of inflammation in 
obesity, diabetes and autoimmune diseases. However, immunosuppression may also 
increase the risk of infections.  
DPA 
Little is known about the effects of DPA because few studies have been conducted, but lately 
interest in this fatty acid has increased because human milk contains high concentration of 
DPA (Yu et al., 1998). From studies performed so far, it has been suggested that DPA could 
act as a lipase inhibitor since faecal excretion of DPA was 4.6 fold higher than equivalent 
  
VKM Report 2015: 27  40 
 
amounts of EPA. However, the incorporation of DPA and EPA in plasma TAGs were similar 
which was explained by EPA being a substrate for β-oxidation.  
DHA 
DHA can be transformed into a variety of metabolites such as resolvins, epoxides, poxytrins, 
neuroprotectins and maresins, some of which are able to inhibit platelet aggregation at low 
micromolar concentrations responses (Chen et al., 2011; Dobson et al., 2013; Serhan et al., 
2008; Spite et al., 2014). The extent to which their relatively subtle effects on platelet 
function may be of clinical significance is a matter of debate. However, the fact that they 
alter important platelet signalling pathways and thereby may mute haemostatic processes is 
clear. 
One of the described studies in the EFSA (2012) opinion specifically assessed whether DHA 
and EPA could have differential effects on platelet aggregation. In a double-blind placebo-
controlled trial of parallel design, 59 treated hypertensive type 2 diabetic men and 
postmenopausal women were randomised to 4 g/day of EPA, DHA or olive oil (placebo) for 
six weeks. DHA but not EPA supplementation significantly reduced collagen aggregation (by 
16.9%) and TXB2 (by 18.8%), whereas no significant changes were reported in either 
platelet activating factor (PAF)-stimulated platelet aggregation, fibrinolytic function or 
vascular function in either the EPA or DHA groups relative to placebo. However, the EFSA 
(2012) opinion describes another study comparing 4 g/day EPA compared to 4 g/day of fish 
oil in which EPA was found more effective in decreasing platelet aggregation. The latter may 
be a dose effect.  
A reduction in platelet-mediated thrombin generation by which DHA (and EPA) may retard 
haemeostasis is a newly discovered mechanism (Larson et al. 2013). The delayed, but not 
eliminated, thrombin activation can still allow for relatively normal haemostasis while also 
reducing the risk of thrombosis (Wachira et al. 2014). 
N-3 LCPUFA 
Because n-3 LCPUFAs have 5-6 double-bonds these fatty acids could be more prone to 
peroxidation than fatty acids with less double-bonds.  
The main side effect of n-3 LCPUFA supplementation is gastrointestinal discomfort, which 
has been reported by some subjects in all supplementation studies.  
 Vulnerable groups 2.5.5
Concern was raised in an intervention study in children that reported nose bleeding episodes 
associated with the consumption of fish oil (Clarke et al., 1990). In our literature search, no 
new studies reporting on bleeding complication related to EPA or DHA supplementation in 
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children were identified. In a new Danish cross sectional study by (Damsgaard et al., 2014), 
whole blood EPA was positively associated with higher diastolic blood pressure in boys (8 to 
11 years). No information about dietary intake was available in the article. According to the 
authors, similar results were found in a pilot study where increased blood pressure was 
correlated with whole blood DHA concentration (Damsgaard et al., 2014). Respiratory 
distress syndrome was reported in a child born to a mother using 1.8 g EPA from week 31 to 
34 and 2.7 g EPA from week 34 to 37 during pregnancy (Sato et al., 2013). The child 
recovered after 7 days without further need for treatment. This was a case-report and no 
further studies were recognised reporting adverse outcome following supplementation during 
pregnancy. 
2.6 Summary of hazard identification and characterisation 
There are several RCTs studying the effect of n-3 LCPUFAs in combination, but still a 
relatively modest number addressing supplements with the single fatty acids EPA, DPA or 
DHA. Only few studies with EPA, DPA or DHA supplements performed after 2011 have 
addressed possible adverse effects of supplementation (included safety concerns). Most of 
the included studies have investigated dosages that are below or at the dosage considered 
as safe by EFSA. None of the included randomised supplementation studies were undertaken 
in children, adolescents or pregnant women. 
EFSA concluded in 2012 that up to 1.8 g/day of supplemental EPA does not raise safety 
concerns for adults, and up to 1 g/day of DHA does not raise safety concern for the general 
population. EFSA did not conclude for DPA because data was not sufficient for evaluation. 
The safety concerns related to n-3 LCPUFAS combined or as single substances in previous 
reports are related to bleeding complications, immune function, peroxidation and impaired 
glucose or lipid homeostasis. 
For risk assessment of combined mixtures of n-3 LCPUFAs in e.g. fish oil/cod liver oil, see the 
EFSA opinion from 2012 or the VKM assessment from 2011 (EFSA, 2012; VKM, 2011). In the 
reviewed literature of this risk assessment, no studies investigating ratios between EPA, DPA, 
DHA or other fatty acids in mixtures have been identified. 
None of the included studies from our literature searches published from 2011 onwards have 
investigated bleeding complications. The included studies have investigated lipid 
peroxidation, immune function and glucose and lipid homeostasis. None of the studies 
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Four randomised controlled trials and three other human studies were included. Three of the 
RCTs are conducted in patients with hypertriglyceridemia. Dosage used i range from 1.8 to 
3.8 g/day of EPA for 12 weeks. The endpoints include immune function, blood pressure and 
heart rate. Diarrhea, nausea, nasopharyngitis, and arthralgia were the most common 
adverse events and no serious adverse events were reported in any of the four randomised 
controlled studies. Furthermore, adverse events reported were not related to dosage. 
Two of the included randomised studies investigated EPA at doses above 1.8 g/day (1.9-
3.8 g/day) as a single fatty acid. Supplemental intakes of EPA at doses up to about 3.8 g/day 
for 12 weeks did not change glucose homeostasis and similar numbers of nasopharyngitis as 
a measure of immune function were seen in treatment group and placebo (Ballantyne 2010, 
Bays 2011). 
In 2012, EFSA did not draw conclusions concerning the safety of EPA for children or 
adolescents. We have identified only one recent cross-sectional study in children (Damsgaard 
et al., 2014) in which the concentration of EPA in blood in 8 to 11 years old children 
correlated positively with blood pressure in boys. However, since no new studies with EPA 
supplementation have been identified in children or adolescents, no provisional safe level of 
use for children or adolescents can be set. 
Animal studies on EPA have not been included in this report as it was considered that EPA is 
thoroughly investigated in humans.  
In summary; it is well documented that 1.8 g supplemental EPA per day is unlikely to cause 
adverse health effects in adults. In two studies doses up to 3.8 g/day were given for 12 
weeks without reported adverse effects. However, these two studies were of short duration, 
i.e. 12 weeks and studies of longer duration are necessary for an assessment of higher 
intakes of EPA.  
As value for comparison in the risk characterisation of EPA, VKM will use 1.8 g/day. This is 
based on the opinion from EFSA from 2012, and also taking into account newer literature. 
DPA 
Information about effects of DPA is scarce, but one study in 10 healthy normal weight 
women given 2 g of supplemental DPA served for breakfast and followed for 5 hours post- 
prandially indicated a different incorporation of DPA compared with EPA into various cell 
membranes. Furthermore, 2 g/day of DPA inhibited incorporation of other fatty acids into 
chylomicrons (Linderborg et al., 2013). In a study in rats, the different incorporation of DPA 
into the various body compartments was confirmed (Fard et al., 2014). However, the 
importance and relevance of these findings still have to be elucidated.  
In summary, no value for comparison can be established for DPA due to lack of data. 
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DHA 
Although there are several human intervention trials with supplementation of DHA alone, 
studies addressing possible adverse effects of DHA supplements for healthy adults and the 
general population are missing. In 2012, EFSA assessed the impact of DHA supplementation 
on bleeding time, platelet function, glucose homeostasis, LDL-cholesterol, and lipid 
peroxidation. For DHA it was concluded that supplemental intakes of DHA up to about 4 g 
per day are not considered to cause adverse effects; it was not associated with an increased 
risk of clinical complications (e.g. spontaneous bleeding). Regarding possible increase in LDL-
cholesterol it was concluded that supplemental intakes of 2 to 4 g DHA per day is not 
adverse in relation to CVD risk. A supplemental intake of up to about 4 g DHA per day for six 
weeks did not induce lipid peroxidation as assessed by F2-isoprostanes. Moreover, doses up 
to about 5 g DHA per day for up to 16 weeks did not induce changes in lipid peroxidation. 
Their final conclusion was that supplemental intakes of up to 1 g/day of DHA do not raise 
safety concerns for the general population. No information was provided regarding how they 
reached their conclusion of up to 1 g DHA per day. 
In this risk assessment, we have included seven studies with both patients and healthy 
adults (Table 2.5-2). The dosages of DHA ranged from 1.0 to 3.6 g DHA/day and the 
duration from five weeks to four years. Six out of seven studies used dosages from 1 to 2 g 
DHA/day. The last study included up to 3.6 g DHA/day for four years and the age spanned 
from 7 to 31 years, but there were few participants, n=33 in the treatment groups. The main 
endpoints in all studies included lipid peroxidation, inflammation, cognitive performance, 
blood pressure, and/or biomarkers of cardiovascular diseases. No serious adverse events 
were found related to the main endpoints. In general, adverse events were described as 
gastrointestinal discomfort and were not related to dose. 
In this report, one safety study of supplemental DHA on vulnerable groups such as pregnant 
women, children and adolescents was identified. Animal studies on DHA have not been 
included in this report as previous risk assessments have found no serious adverse events 
with doses of DHA up to 5 g per day and combined doses of EPA and DHA up to 6.9 g/day 
(VKM 2011, EFSA 2012). 
In summary; due to a limited number of studies with supplemental doses above 1 g DHA per 
day, the risk associated with supplemental DHA above 1 g DHA per day could not be 
assessed. However, a daily dose of DHA that moderately exceed 1.0 g from food 
supplements is not considered to lead to adverse health effects in the general population 
(including children ≥10 years and adolescents). 
As value for comparison in the risk characterisation of DHA, VKM will use 1 g/day. This is 
based on the opinion from EFSA from 2012, and also taking into account newer literature. 
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3 Exposure / Intake 
Exposures of EPA, DPA and DHA were estimated from the intake of food supplements. For 
food supplements, the intakes of EPA, DPA and DHA were estimated for the age groups 10-
14 years, 14-18 years and adults (≥ 18 years). 
3.1 Food supplements 
NFSA requested VKM to perform a risk assessment of 1500, 1750 and 1825 mg/day of EPA, 
100, 125 and 150 mg/day of DPA and 1050 and 1290 g/day of DHA in food supplement for 
children 10 years and above, adolescents and adults. The default body weights (bw) for age 
groups determined by EFSA were used: 10 to<14 years = 43.4 kg, 14 to <18 years = 
61.3 kg and adults = 70.0 kg. The estimated exposures from supplemental EPA, DPA and 
DHA in children, adolescents and adults are given in Table 3.1-1. 
Table 3.1-1  Estimated exposure of EPA, DPA and DHA in children, adolescents and adults from 
food supplements. 
Information about intakes of EPA, DPA and DHA from the diet is scarce, but calculations 
performed in the Norwegian Mother and Child Cohort Study indicate a mean total intake (SD) 
from food and supplements of EPA around 330 (340) mg/day, DPA 43 (30) mg/day and DHA 
430 (380) mg/day among pregnant women (2002 to 2008), see Table 3.1-2. 
Groups Daily doses (mg) Body 
weight 
(kg) 
Exposure (mg/kg bw per 
day) 
Children (10 to 
<14years) 
EPA 1500, 1750 and 1825 
DPA 100, 125, 150 
DHA 1050, 1290 
43.4 EPA: 35, 40 and 42  
DPA: 2.3, 2.9 and 3.5  
DHA: 24 and 30 
Adolescent (14 to 
<18 years) 
EPA 1500, 1750 and 1825 
DPA 100, 125, 150 
DHA 1050, 1290 
61.3 EPA: 25, 29 and 30  
DPA: 1.6, 2.0 and 2.4  
DHA: 17 and 21 
Adults (≥18 years) EPA 1500, 1750 and 1825 
DPA 100, 125, 150 
DHA 1050, 1290 
70.0 EPA: 21, 25 and 26 
DPA: 1.4, 1.8 and 2.1 
DHA: 15 and 18 
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Mean intake of EPA, DPA and DHA from fish oil/ cod liver oil in adults participating in a 
nationally representative dietary survey was 735 mg/day (VKM, 2014). 
Concentrations of the n-3 LCPUFAS in cod liver oil may vary, and a recommended dose of 
5 ml may contain 400 mg EPA, 60 mg DPA and 600 mg DHA. 
3.2 Other sources 
Use of EPA, DPA or DHA as single fatty acids in a supplement is relatively new and the actual 
intake and usage is not known in the general Norwegian population.  
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4 Risk characterisation  
EPA  
The doses requested from NFSA are 1500, 1750 and 1825 mg EPA per day in food 
supplements, and the exposures for children (10 years and above), adolescents and adults 
are given in chapter 3.  
The value for comparison used in this risk characterisation of EPA is 1.8 g/day. 
Two supplementation studies with 3.8 g EPA per day for 12 weeks did not report adverse 
effects, but these studies were of too short durations to conclude on chronic effect. VKM 
however, considers that the highest specified daily dose of EPA 1825 mg/day is unlikely to 
cause adverse health effects. 
One study included children aged 8 to 11 years, in which a positive association was found 
between EPA blood concentration and blood pressure in boys, indicating that children might 
be more vulnerable than adults for high body concentrations of EPA. However, this was not a 
supplementation study and the authors also reported on uncontrolled situations when blood 
pressure was measured. No safe level for EPA supplementation in children or adolescents 
was set in the EFSA report from 2012. Taken together, the EFSA conclusion from 2012 and 
newer studies in children no risk characterisation can be made for children and adolescents 
with regard to EPA supplementation.  
VKM considers that: 
In adults, (18 years and above) the specified doses of 1500, 1750 and 1825 mg EPA in food 
supplements are unlikely to cause adverse health effects. 
No safe dose can be stated for children and adolescents because of insufficient data.  
DPA 
The doses requested from NFSA are 100, 125 and 150 mg DPA per day in food supplements, 
and the exposures for children, adolescents and adults are given in chapter 3. For DPA there 
is not sufficient data to assess the risk of adverse effects for any population group. 
DHA 
The doses received from NFSA are 1050 and 1290 mg DHA per day in food supplements, 
and the exposures for adults, children (10 years and above) and adolescents are given in 
chapter 3. 
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The value for comparison used in this risk characterisation of DHA is 1 g/day. This value is 
valid for the general population (including children 10 years and above and adolescents). 
A previous risk assessment report (EFSA, 2012) has concluded that doses up to 1 g DHA/day 
do not raise safety concern for the general population. However, in the same report no 
serious adverse events were described with supplemental intakes up to 5 g DHA per day. In 
the present risk assessment, the included studies encompass adults and children, both 
patient groups and healthy subjects, and the dosages of DHA range from 1.0 to 3.6 g/day 
with duration of interventions ranging from five weeks to four years. VKM therefore 
considers that the specified daily doses of DHA, 1050 and 1290 mg/day, are unlikely to 
cause adverse health effects in adults, children (10 years and above) and adolescents. 
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5 Uncertainties 
No studies on children and adolescents were identified in the new literature search and it is 
therefore possible only to make assumptions about the safety for these groups. 
The risk assessment is based on previous risk assessments of EPA, DPA and DHA containing 
no information on vulnerable groups, interactions or allergy. 
The majority of the studies considered are studies specifically designed to investigate 
positive effects such as reduction of hypertriglyceridemia and depression or cognitive 
impairment and do not focus on adverse health effects. In the human studies, the adverse 
effects reported are mainly based on self-reporting questionnaires, and to lesser extent 
biomarkers for negative health effects e.g. bleeding time, peroxidation or immune function. 
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6 Data gaps 
The few studies on negative health effects related to supplemental intake of EPA or DHA are 
only performed in different patient groups and have high heterogeneity in both design and 
results, and are limited to adults with the exception that one study includes patients aged 7-
31 years. The majority of studies are of short duration, mostly 12 weeks, and studies of one 
to two years duration are lacking.  
There is a general lack of studies addressing supplemental use of individual n-3 LCPUFAs in 
vulnerable groups such as pregnant women and children. 
There are generally lacking safety studies related to supplemental intakes of either EPA, DPA 
or DHA, particularly in children, adolescents and pregnant women. 
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7 Conclusions with answers to the 
terms of reference 
The Norwegian Food Safety Authority (NFSA) requested the Norwegian Scientific Committee 
for Food Safety (VKM) to assess the safety of EPA, DPA and DHA in food supplements at the 
following doses for the general population, ages 10 years and above: 
EPA: 1500, 1050 and 1825 mg/day 
DPA: 100, 125 and 150 mg/day 
DHA: 1050 and 1290 mg/day 
It is emphasised that this risk assessment concerns the single fatty acids EPA, DPA or DHA 
separately and not mixtures of these as found in e.g. fish oil/cod liver oil. For risk 
assessment of combined mixtures of n-3 LCPUFAs in e.g. fish oil/cod liver oil, see the EFSA 
opinion from 2012 or the VKM assessment from 2011 (EFSA, 2012; VKM, 2011). In the 
reviewed literature of this risk assessment, no studies investigating ratios between EPA, DPA, 
DHA or other fatty acids in mixtures have been identified. 
In the EFSA report 2012 it was concluded that doses up to 1.8 g per day of EPA in adults 
and 1 g per day of DHA in adults, adolescents and children for one year is unlikely to cause 
adverse health effects.  
Some adverse health effects related to gastrointestinal function, including abdominal cramps, 
flatulence, eructation, vomiting and diarrhea have been reported in the reviewed literature, 
but seem to be associated with intake of an oily substance and not related specifically to 
EPA, DPA and/or DHA. 
The major concerns with high intake of EPA or DHA have been increased bleeding time or 
related to immune function, lipid peroxidation and glucose homeostasis. 
Due to lack of clinical studies and/ or randomised controlled trials, vulnerable groups like 
pregnant /lactating women have not been evaluated in this report. 
VKM concludes that: 
 The specified daily doses of 1500, 1750 or 1825 mg/day of EPA in food supplements 
are unlikely to cause adverse health effects in adults (≥18 years). 
 No conclusion can be made for children or adolescents for EPA. 
 No dosage of DPA in food supplements can be evaluated due to lack of data. 
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 The specified daily doses of 1050 and 1290 mg/day of DHA in food supplements are 
unlikely to cause adverse health effects in the general population including children 
(≥10 years), adolescents and adults (≥18 years).  
 
An overview of the conclusions is presented in Table 7.1. 
Table 7.1: An overview of the conclusions for EPA and DHA in food supplements.  
Green: Estimated exposures to EPA or DHA are unlikely to cause adverse health effects. 
Grey: No conclusions have been made. 
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9 Appendix 
Strategy for main literature search 
Database: Ovid MEDLINE(R) <1946 to April Week 4 2015>, Embase <1974 to 2015 April 
30> 
-------------------------------------------------------------------------------- 
1. eicosapentaen*.ti. (3583) 
2. EPA.ti. (2549) 
3. docosahexaen*.ti. (5133) 
4. DHA.ti. (1959) 
5. docosapentaen*.ti. (166) 
6. DPA.ti. (383) 
7. 1 or 2 or 3 or 4 or 5 or 6 (11830) 
8. (risk* or safety or adverse or side-effect*1 or hazard* or harm* or bleeding* or 
negative or contraindicat* or contra-indicat* or interact* or toxicity or toxic).tw. 
(8874887) 
9. 7 and 8 (2467) 
10. (conference abstract* or letter* or editorial*).pt. (4382040) 
11. not 10 (2158) 
12. limit 11 to (danish or english or norwegian or swedish) (2092) 
13. limit 12 to human (1298) 
14. remove duplicates from 13 (747) 
15. limit 14 to yr="2011 -Current" (252) 
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Strategies additional literature searches for EPA, DPA and DHA, 
respectively, and children and adolescents 
Database: Ovid MEDLINE(R) <1946 to June Week 1 2015>, Embase <1974 to 2015 June 
04> 
-------------------------------------------------------------------------------- 
1. (eicosapentaenoic acid* or EPA).ti. (5448) 
2. (child* or adolescent* or teenage* or college* or high school*).mp. [mp=ti, ab, ot, 
nm, hw, kf, px, rx, ui, an, tn, dm, mf, dv, kw] (5855060) 
3. 1 and 2 (214) 
4. (conference abstract* or letter* or editorial*).pt. (4464924) 
5. 3 not 4 (175) 
6. limit 5 to (danish or english or norwegian or swedish) (172) 
7. limit 6 to human (164) 
8. remove duplicates from 7 (118) 
9. limit 8 to yr="2011 -Current" (29) 
Database: Ovid MEDLINE(R) <1946 to June Week 1 2015>, Embase <1974 to 2015 June 
04> 
1. (docosahexaenoic acid* or DHA).ti. (6358) 
2. (child* or adolescent* or teenage* or college* or high school*).mp. [mp=ti, ab, ot, 
nm, hw, kf, px, rx, ui, an, tn, dm, mf, dv, kw] (5855060) 
3. 1 and 2 (552) 
4. (conference abstract* or letter* or editorial*).pt. (4464924) 
5. 3 not 4 (454) 
6. limit 5 to (danish or english or norwegian or swedish) (433) 
7. limit 6 to human (397) 
8. remove duplicates from 7 (252) 
9. limit 8 to yr="2011 -Current" (91) 
Database: Ovid MEDLINE(R) <1946 to June Week 1 2015>, Embase <1974 to 2015 June 
04> 
-------------------------------------------------------------------------------- 
1. (docosapentaenoic acid* or DPA).ti. (524) 
2. (child* or adolescent* or teenage* or college* or high school*).mp. [mp=ti, ab, ot, 
nm, hw, kf, px, rx, ui, an, tn, dm, mf, dv, kw] (5855060) 
3. 1 and 2 (43) 
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4. (conference abstract* or letter* or editorial*).pt. (4464924) 
5. 3 not 4 (41) 
6. limit 5 to (danish or english or norwegian or swedish) (21) 
7. limit 6 to human (18) 
8. remove duplicates from 7 (10) 
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Strategy for additional literature search for DPA including 
animal studies 
Database: Ovid MEDLINE(R) <1946 to June Week 1 2015>, Embase <1974 to 2015 June 
16> 
-------------------------------------------------------------------------------- 
1. docosapentaenoic acid*.ti. (147) 
2. dokosapentaensyre*.ti. (0) 
3. 1 or 2 (147) 
4. remove duplicates from 3 (82) 
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